Form 4 for NVCR NovoCure Ltd
Accepted 2022-03-11 00:00:00 ET · period of report 2021-07-31 · accession 0001645113-22-000031 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-11 | 2022-03-09 | NVCR | Shah Pritesh | Chief Commercial Off | S - Sale+OE | $71.19 | -3,669 | 83.2K | -4% | -$261.2K |
| D | 2022-03-11 | 2021-07-31 | NVCR | Shah Pritesh | Chief Commercial Off | M - OptEx | $154.01 | +3,717 | 85.6K | +5% | +$572.5K |
| D | 2022-03-11 | 2021-07-31 | NVCR | Shah Pritesh | Chief Commercial Off | M - OptEx | $0.00 | -3,717 | 3,717 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-03-09 | S | D | 3,669 | $71.19 | 83,187 | D | — | — | (F1) Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. (F2) Amended total to correct prior mathematical error. |
| 2 | Common | Ordinary Shares | 2021-07-31 | M | A | 3,717 | $154.01 | 85,625 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2021-07-31 | M | D | 3,717 | $0.00 | 3,717 | D | $0.00 · 2021-07-31 to — | 3,717 Ordinary Shares | (F3) Fully vested as of the date hereof. |